KWKeele E. Wurst

Keele E. Wurst

*This is an algorithmically generated author record based on publicly available information.

Keele E. Wurst has a total of 122 co-authors. Here are the top co-authors by number of shared publications:

  • Sara A. Ephross

    GlaxoSmithKline Research Triangle Park NC USA

    4 shared publications
  • Amit Shukla

    Worldwide Epidemiology, GlaxoSmithKline R&D, Upper Providence, Pennsylvania, United States of America

    3 shared publications
  • Betsy Sleath

    University of North Carolina at Chapel Hill, USA

    3 shared publications
  • Hana Muellerova

    Real-World Evidence&Epidemiology, GSK R&D, Uxbridge, UK

    3 shared publications
  • Andrew F. Olshan

    Department of Epidemiology, University of North Carolina, Chapel Hill, North Carolina

    2 shared publications
  • Brian T. Bateman

    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass; Department of Anesthesiology, Critical Care, and Pain Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Mass

    2 shared publications

Latest Publications

  • Open Access

    Incidence and prevalence of connective tissue disease (CTD)-associated interstitial lung disease in the United States

    by Diana Martins, George Mu, Elaine Irving, Sally Wetten, Roger A. Levy, Keele Wurst

    Objectives: Interstitial lung disease (ILD) is a pulmonary manifestation of connective tissue diseases (CTDs). Limited data exist describing the epidemiology of CTD-ILD; therefore, this study aimed to estimate the incidence and prevalence of CTD-ILD in the US, overall and by CTD-ILD subtypes. Methods: Patients with CTD-ILD and rheumatoid arthritis (RA), systemic sclerosis (SSc), systemic lupus erythematosus (SLE), idiopathic inflammatory myopathy (IIM), mixed CTD (MCTD), and Sjögren’s disease (SjD) were identified from Optum ® de-identified Electronic Health Record data set (Optum ® EHR) and MarketScan ® Commercial and Medicare US databases between 2019 and 2024. Results: ILD was present in 4.3% (n = 21,366/496,690; Optum ® EHR) and 3.2% (n = 7521/234,468; MarketScan) of identified patients with CTD. This proportion was highest for those with SSc (Optum ® EHR: 20.3%; MarketScan: 21.1%). Most patients with CTD-ILD were female in both Optum ® EHR and MarketScan, with median ages 64 and 56 years, respectively; race was available only in Optum ® EHR, where 72.1% were categorized as Caucasian. Age- and sex-adjusted incidence rates were 7.6 and 10.0 per 100,000 person-years, with adjusted prevalence rates 46.7 and 43.4 per 100,000 persons. Rates varied by CTD subtype and were highest for RA-ILD and lowest for MCTD-ILD across databases. Crude rates of CTD-ILD regardless of subtype were higher among female patients, patients aged ≥ 65 years, and among patients of Black African ancestry. Conclusion: Consistent age- and sex-adjusted CTD-ILD incidence and prevalence estimates between two large, demographically distinct US databases provide contemporary population-level estimates of CTD-ILD frequency and distribution that can inform disease screening and patient care. Key points • US CTD-ILD incidence estimated at 7.6 and 10.0/100,000 person-years and prevalence estimated at 46.7 and 43.4/100,000 persons. • Incidence and prevalence rates were highest in female patients, patients aged ≥ 65 years, and patients of Black African ancestry. • Incidence and prevalence rates varied between CTD subtypes and were highest for RA-ILD and lowest for MCTD-ILD.

  • Challenges and Insights from the Mepolizumab Pregnancy Exposure Study

    by Keele E. Wurst, Michael Schatz, Subramanya Kumar, Megan Delgado, Christina D. Chambers

  • Off‐the‐Shelf Large Language Models for Guiding Pharmacoepidemiological Study Design

    by Gerard Ompad, Keele Wurst, Darmendra Ramcharran, Anders Hviid, Andrew Bate, Maurizio Sessa

    This study aimed to assess the ability of two off‐the‐shelf large language models, ChatGPT and Gemini, to support the design of pharmacoepidemiological studies. We assessed 48 study protocols of pharmacoepidemiological studies published between 2018 and 2024, covering various study types, including disease epidemiology, drug utilization, safety, and effectiveness. The coherence (i.e., “Is the response coherent and well‐formed, or is it difficult to understand?”) and relevance (i.e., “Is the response relevant and informative, or is it lacking in substance?”) of the large language models' responses were evaluated by human experts across seven key study design components. Coding accuracy was assessed. Both large language models demonstrated high coherence, with over 90% of study components rated as “Strongly agree” by experts for most categories. ChatGPT achieved the highest coherence for “Index date” (97.9%) and “Study design” (95.8%). Gemini excelled in “Study outcome” (93.9%) and “Study exposure” (95.9%). Relevance, however, was more variable, with ChatGPT aligning with expert recommendations in over 90% of cases for “Index date” and “Study design” but showing lower agreement for covariates (65%) and follow‐up (70%). Coding agreement percentages reveal varying levels of concordance, with the Anatomical Therapeutic Chemical classification system coding system demonstrating the highest agreement at 50% with experts. In contrast, the Current Procedural Terminology and International Classification of Diseases systems showed agreements of 22.2% and 20%, respectively. While ChatGPT and Gemini show promise in certain tasks supporting pharmacoepidemiological study design, their limitations in relevance and coding accuracy highlight the need for critical oversight by domain experts.


  • Open Access

    Use of Sotrovimab in Pregnancy: Experiences from the COVID-19 International Drug Pregnancy Registry

    by Diego F. Wyszynski, Lydia Demetriou, Cheryl Renz, Shirin Aliabadi, Dragutin Rafailovic, Lee P. Shulman, Myriam Drysdale, Keele E. Wurst

    Introduction Available data regarding the safety and efficacy of sotrovimab in pregnant patients remain limited due to their exclusion from clinical trials. Methods The COVID-19 International Drug Pregnancy Registry (COVID-PR) was established to gather comprehensive safety data from pregnant women who have received monoclonal antibody (mAb) or antiviral treatments for mild, moderate, or severe coronavirus disease 2019 (COVID-19) during pregnancy. Participants actively contributed self-reported data concerning their COVID-19 symptoms, in addition to sociodemographic and health-related characteristics. Obstetric, neonatal, and infant outcomes were also documented, with follow-up extending up to 12 months after childbirth. Results As of 30 November 2023, sotrovimab was administered to 39 participants enrolled in the COVID-PR. At the time of this report, 26 participants had given birth, with nine deliveries performed via cesarean section. The infants’ birthweight ranged from 2381 g to 4762 g, with a mean of 3439.91 g. Twenty-five infants were born at ≥37 weeks. A total of 31 adverse events (AEs) were reported by 12 participants. The most frequently reported AE was gestational hypertension, observed in three participants. COVID-19 re-infection, fatigue, gestational diabetes, headache, and morning sickness were each reported by two participants. Of the reported AEs, eight (in five participants) were classified as serious, including four AEs (prolonged labor, pre-eclampsia, polyhydramnios, premature labor) that affected pregnancy. Seven of these eight serious AEs (SAEs) were found to be unrelated to sotrovimab, with one event (urinary retention) not assessable. A total of 44 AEs were reported in 19 delivered infants or in utero fetuses. The most common were COVID-19 (n = 6 events), ear infection (n = 5 events), neonatal dyspnea (n = 3 events), and respiratory syncytial virus infection (n = 3 events). Sixteen AEs (in 11 infants/fetuses) were classified as serious, including one report each of fetal cardiac disorder, congenital ankyloglossia, persistent right umbilical vein, and congenital hydronephrosis; the latter was considered a major congenital malformation. For all assessable SAEs, causality of sotrovimab treatment was ruled out based on lack of a temporal relationship alone or in combination with absence of a plausible mechanism. Conclusion A sizable proportion of sotrovimab-treated participants in the COVID-PR had underlying medical conditions associated with an increased risk of severe COVID-19. None of the assessable SAEs were considered to be related to sotrovimab treatment.


  • Open Access

    Drug Utilization Studies in Pregnant Women for Newly Licensed Medicinal Products: A Contribution from IMI ConcePTION

    by Sandra Lopez-Leon, Anja Geldhof, Julie Scotto, Keele Wurst, Meritxell Sabidó, Jingping Mo, Ditte Molgaard-Nielsen, Jorieke E. H. Bergman, Xuan Anh Phi, Sue Jordan

    Purpose. Studies focusing on safety outcomes typically require large populations to comprehensively characterise the patient groups exposed to the medicines under investigation. However, there is often less information for subpopulations, such as pregnant or breastfeeding women, particularly when new medicines are considered. It is important to understand what information can be obtained from drug utilization studies (DUS) involving pregnant women in the early years postmarketing to provide supportive information for safety studies. The aims of this literature review are to (1) identify and review DUS for new medicines in pregnancy and breastfeeding and (2) list and summarise key information items to be reported in a DUS for new medicines in pregnancy. Methods. To identify postmarketing DUS of new prescription medicines or enantiomers in pregnancy, a systematic literature review was undertaken in PubMed and Embase between January 2015 and June 2022. In addition, the complete database of the ENCePP EU PAS Register was systematically searched to June 2022. Results. We identified 11 published DUS on new medicines in pregnancy from the ENCePP EU PAS Register and none from other sources. No studies on breastfeeding were identified. The 11 identified publications reported the medicine’s use for the first 3 to 5 years after marketing approval. No reports assessed utilization in the first 3 years of approval. It was usual to issue interim reports annually (7 studies). All studies concerned conditions managed in ambulatory care (primary care and outpatient facilities) and included some primary care prescribing. Most ( ) only had prescribing/dispensing data available at individual level for ambulatory care; outpatient prescribing was included in three of these studies Three studies held a limited amount of in-hospital prescribing data. A DUS can confirm at an early stage whether there are sufficient exposed pregnancies in available data sources to ensure a safety study is powered to detect a difference in the prevalence of adverse pregnancy or infant outcomes or if additional data from other databases are needed. A DUS may also help address methodological considerations such as selection of comparators. DUS can be performed embedded in a DUS in the general population, in a cohort of women of childbearing age, or in a cohort of pregnant women. Conclusion. This review summarises key aspects of a DUS for new medicines in pregnancy. DUS for new medicines in pregnancy should be planned before marketing, scheduled for the first 3 to 5 years after release, with annual interim/progress reports, and reported in peer-reviewed journals. By offering detailed information on data sources, exposure timing, prevalence and location, coprescribing, comorbidities, coexposures, and demographics, a DUS will offer a firm foundation for safety studies and will help to contextualize spontaneous reporting of serious adverse events.


  • Open Access

    Belimumab use during pregnancy: Interim results of the belimumab pregnancy registry

    by Patricia Juliao, Keele Wurst, Jeanne M. Pimenta, Kim Gemzoe, Helain Landy, M. Anthony Moody, Hugh Tilson, Deborah Covington, Tammy Moore, Rebecca Marino, et al.

    Background: Belimumab is approved for active, autoantibody‐positive systemic lupus erythematosus (SLE) and lupus nephritis, but limited data exist regarding its use in pregnancy. The Belimumab Pregnancy Registry (BPR, GSK Study BEL114256; NCT01532310) was created to evaluate pregnancy and infant outcomes following belimumab exposure.Methods: Individuals with SLE exposed to belimumab from 4 months before and/or during pregnancy can enroll into the BPR. The primary outcome is major birth defects; secondary outcomes include miscarriages, stillbirths, elective termination, pre‐term birth, neonatal death, small for gestational age, and adverse infant outcomes during the first year of life. Belimumab exposure timing, concomitant medications, and other potential confounding factors are also collected. Data up to March 8, 2021, are reported descriptively.Results: From an expected sample size target of 500 prospective pregnancies with a known outcome, only 55 were enrolled in the study. Among these, two pregnancy losses and 53 pregnancies with a live birth outcome were reported. Ten of the 53 live birth pregnancies resulted in a major birth defect. Ten pregnancies were enrolled after the pregnancy outcome occurred and were examined retrospectively (four live births with no defects, four miscarriages, and two elective terminations). There was no indication or pattern of birth defects associated with belimumab.Conclusions: Low recruitment numbers for the BPR and incomplete information limit the conclusions regarding belimumab exposure during pregnancy. There was no pattern or common mechanism of birth defects associated with belimumab within the BPR data.


  • Development and evaluation of standardized pregnancy identification and trimester distribution algorithms in U.S. IBM MarketScan® Commercial and Medicaid data

    by Kelsey M. Sumner, Anna Ehlinger, Mary E. Georgiou, Keele E. Wurst

    Objectives: Creation of new algorithms to identify pregnancies in automated health care claims databases is of public health importance, as it allows us to learn more about medication use and safety in a vulnerable population. Previous algorithms were largely created using international classification of disease codes, but despite the U.S. code transition in 2015, few algorithms are available with the latest ICD‐10‐CM codes.Methods: Using U.S. IBM MarketScan® Commercial Claims and Encounters and Multi‐State Medicaid databases for women aged 10–64 years during 2014 and 2016, two pregnancy algorithms (ICD‐9‐CM and ICD‐10‐CM) were created using expert clinical review. The algorithms were evaluated by assessing the distribution of pregnancy outcomes (live birth and pregnancy losses) within each time‐based cohort and the ability of the algorithms to identify select medication use during pregnancy. Medication exposure, demographics, comorbidities, and pregnancy outcomes were compared to published literature estimates for the two time periods.Results: For the IBM MarketScan® Commercial database, the algorithms identified 687,228 pregnancies in 2014 and 444,293 in 2016. In the IBM MarketScan® Medicaid database, 389,132 pregnancies in 2014 and 406,418 in 2016 were identified. Percentages of most pregnancy outcomes identified using the algorithms were similar to national data sources; however, percentages of preterm births and pregnancy losses were not comparable. Most medication use estimates from the algorithms were similar to or higher than published estimates.Conclusions: By incorporating the latest ICD‐10‐CM codes, the new algorithms provide more complete estimates of medication use during pregnancy than algorithms using the outdated codes.


  • A model for human and animal data integration: Weight of evidence strategy

    by Keele E. Wurst, Kelsey M. Sumner, Dinesh Stanislaus, Marcy Powell, Marianne Cunnington

    Background Integration of animal and human data to assess potential risks of the use of medications in pregnancy is important. A qualitative weight of evidence process enables all available evidence to be considered in a consistent, systematic manner. Methods We aim to describe the weight of evidence methodology utilized by the authors, a summary of which was presented at the 59th Annual Meeting of the Teratology Society entitled “Integration of Human and Animal Data to Inform Medication Use in Pregnant Women.” The qualitative weight of evidence process evaluates data that inform on a potential relationship between an adverse pregnancy outcome and a medication exposure. An interdisciplinary panel evaluates all available human and animal data related to the question of interest. Study quality assessments of both human and animal data are incorporated. The evaluation assesses gaps in the data from the following areas: (a) strength, (b) specificity, (c) consistency, (d) dose response relationship, (e) methodological considerations, and (f) biological plausibility for the potential association of interest. Results The panel integrates all the information to arrive at an assessment of the evidence and provides recommendations, which may include obtaining more specific information. We provide examples of how the authors apply this process at a pharmaceutical company for evaluation of potential postmarketing safety issues regarding medications and pregnancy outcomes. Conclusions This weight of evidence method improves the ability to integrate published literature and other data sources to assess the potential risks of medication use in pregnant women and inform future drug safety studies.


  • Perinatal Outcomes Associated with Maternal Asthma and Its Severity and Control During Pregnancy

    by Jennifer J. Yland, Brian T. Bateman, Krista F. Huybrechts, Gregory Brill, Michael X. Schatz, Keele E. Wurst, Sonia Hernández-Díaz


  • Poorly Controlled Asthma During Pregnancy Remains Common in the United States

    by Jacqueline M. Cohen, Brian T. Bateman, Krista F. Huybrechts, Helen Mogun, Jennifer Yland, Michael Schatz, Keele E. Wurst, Sonia Hernandez-Diaz